Differentiating effect of thalidomide and GM-CSF combination on HL-60 acute promyelocytic leukemia cells

Experimental Oncology

Volumn 28, Issue 3, 2006, Pages 216-219

  Ural, A U ^a   Avcu, F ^a   Zerman, M ^a   Yilmaz, M I ^a   Pekel, A ^a   Beyzadeoglu, M ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Apoptosis; Differentiation; GM CSF; HL 60; Thalidomide

Indexed keywords

ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; PROPIDIUM IODIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PROMYELOCYTIC LEUKEMIA;

ANTIGENS, DIFFERENTIATION; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; THALIDOMIDE;

EID: 33750935096     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol 1999; 27: 885-94.
2. Blalock WL, Weinstein-Oppenheimer C, Chang F. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109-66.
3. Breitman TR, He RY. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 50: 6268-73.
4. Colombat P, Santini V, Delwel R, Krefft J, Bredmond JL, Lowenberg B. Primary human acute myeloblastic leukaemia: an analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. Br J Haematol 1991; 79: 382-9.
5. Hideshima T, Chauhan D, Shima Y. Thalidomide and its analog overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000; 96: 2943-50.
6. Kimby E, Nygran P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukemia. Acta Oncol 2001; 40: 231-52.
7. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996; 81: 219-23.
8. Matsui WH, Gladstone DE, Vala MS, Barher JP, Brodsky RA, Smith BD, Jones RJ. The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ 2002; 13: 275-83.
9. Rots NY, Iavarone A, Bromleigh V, Freedman LP. Induced differentiation of U937 cells by 1,25-dihydroxyvitamin D3 involves cell cycle arrest in G1 that is preceded by a transient proliferative burst and an increase in cyclin expression. Blood 1999; 93: 2721-9.
10. Shinjo K, Takeshita A, Ohnishi K, Ohno R. Granulocyte colony-stimulating factor receptor at various differentiation stages of normal and leukemic hematopoietic cells. Leuk Lymphoma 1997; 25: 37-46.
11. Shoji M, Fukuhara T, Winton EF, Berdel WE, Vogler WR. Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines. Exp Hematol 1994; 22: 13-8.
12. Steins MB, Padro T, Bieker R. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834-9.
13. Studzinski GP, Harrison LE. Differentiation-related changes in the cell cycle traverse. Int Rev Cytol 1999; 189: 1-58.
14. Thomas DA, Estey E, Giles FJ. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol 2003; 123: 436-41.
15. Ural AU, Yilmaz MI, Avcu F, Ozcan A, Ide T, Kurt B, Yalcin A. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int J Hematol 2003; 78: 443-9.
16. Valtieri M, Boccoli G, Testa U, Barletta C, Peschle C. Two-step differentiation of AML-193 leukemic line: terminal maturation is induced by positive interaction of retinoic acid with granulocyte colony-stimulating factor (CSF) and vitamin D3 with monocyte CSF. Blood 1991; 77: 1804-12.